RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Jose L. Lopez-Ribot to Animals

This is a "connection" page, showing publications Jose L. Lopez-Ribot has written about Animals.
Connection Strength

0.812
  1. Romo JA, Lopez-Ribot JL. Candidalysin: An unlikely aide for fungal gut commensalism. Cell Host Microbe. 2024 May 08; 32(5):625-626.
    View in: PubMed
    Score: 0.074
  2. Ajetunmobi OH, Chaturvedi AK, Badali H, Vaccaro A, Najvar L, Wormley FL, Wiederhold NP, Patterson TF, Lopez-Ribot JL. Screening the medicine for malaria venture's Pandemic Response Box to identify novel inhibitors of Candida albicans and Candida auris biofilm formation. APMIS. 2023 Nov; 131(11):613-625.
    View in: PubMed
    Score: 0.070
  3. Romo JA, Pierce CG, Chaturvedi AK, Lazzell AL, McHardy SF, Saville SP, Lopez-Ribot JL. Development of Anti-Virulence Approaches for Candidiasis via a Novel Series of Small-Molecule Inhibitors of Candida albicans Filamentation. mBio. 2017 Dec 05; 8(6).
    View in: PubMed
    Score: 0.048
  4. Vila TV, Chaturvedi AK, Rozental S, Lopez-Ribot JL. In Vitro Activity of Miltefosine against Candida albicans under Planktonic and Biofilm Growth Conditions and In Vivo Efficacy in a Murine Model of Oral Candidiasis. Antimicrob Agents Chemother. 2015 Dec; 59(12):7611-20.
    View in: PubMed
    Score: 0.041
  5. Pierce CG, Srinivasan A, Uppuluri P, Ramasubramanian AK, L?pez-Ribot JL. Antifungal therapy with an emphasis on biofilms. Curr Opin Pharmacol. 2013 Oct; 13(5):726-30.
    View in: PubMed
    Score: 0.035
  6. Pierce CG, Lopez-Ribot JL. Candidiasis drug discovery and development: new approaches targeting virulence for discovering and identifying new drugs. Expert Opin Drug Discov. 2013 Sep; 8(9):1117-26.
    View in: PubMed
    Score: 0.035
  7. Uppuluri P, Chaturvedi AK, Jani N, Pukkila-Worley R, Monteagudo C, Mylonakis E, K?hler JR, Lopez Ribot JL. Physiologic expression of the Candida albicans pescadillo homolog is required for virulence in a murine model of hematogenously disseminated candidiasis. Eukaryot Cell. 2012 Dec; 11(12):1552-6.
    View in: PubMed
    Score: 0.033
  8. Chaturvedi AK, Lazzell AL, Saville SP, Wormley FL, Monteagudo C, Lopez-Ribot JL. Validation of the tetracycline regulatable gene expression system for the study of the pathogenesis of infectious disease. PLoS One. 2011; 6(5):e20449.
    View in: PubMed
    Score: 0.030
  9. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, K?hler JR, Kadosh D, Lopez-Ribot JL. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog. 2010 Mar 26; 6(3):e1000828.
    View in: PubMed
    Score: 0.028
  10. Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother. 2009 Sep; 64(3):567-70.
    View in: PubMed
    Score: 0.027
  11. Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis. Clin Vaccine Immunol. 2009 Mar; 16(3):430-2.
    View in: PubMed
    Score: 0.026
  12. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. Our current understanding of fungal biofilms. Crit Rev Microbiol. 2009; 35(4):340-55.
    View in: PubMed
    Score: 0.026
  13. Lee SA, Jones J, Hardison S, Kot J, Khalique Z, Bernardo SM, Lazzell A, Monteagudo C, Lopez-Ribot J. Candida albicans VPS4 is required for secretion of aspartyl proteases and in vivo virulence. Mycopathologia. 2009 Feb; 167(2):55-63.
    View in: PubMed
    Score: 0.025
  14. Saville SP, Lazzell AL, Chaturvedi AK, Monteagudo C, Lopez-Ribot JL. Use of a genetically engineered strain to evaluate the pathogenic potential of yeast cell and filamentous forms during Candida albicans systemic infection in immunodeficient mice. Infect Immun. 2008 Jan; 76(1):97-102.
    View in: PubMed
    Score: 0.024
  15. Thomas DP, Pitarch A, Monteoliva L, Gil C, Lopez-Ribot JL. Proteomics to study Candida albicans biology and pathogenicity. Infect Disord Drug Targets. 2006 Dec; 6(4):335-41.
    View in: PubMed
    Score: 0.022
  16. Thomas DP, Viudes A, Monteagudo C, Lazzell AL, Saville SP, L?pez-Ribot JL. A proteomic-based approach for the identification of Candida albicans protein components present in a subunit vaccine that protects against disseminated candidiasis. Proteomics. 2006 Nov; 6(22):6033-41.
    View in: PubMed
    Score: 0.022
  17. Monteagudo C, Viudes A, Lazzell A, Martinez JP, Lopez-Ribot JL. Tissue invasiveness and non-acidic pH in human candidiasis correlate with "in vivo" expression by Candida albicans of the carbohydrate epitope recognised by new monoclonal antibody 1H4. J Clin Pathol. 2004 Jun; 57(6):598-603.
    View in: PubMed
    Score: 0.019
  18. Viudes A, Lazzell A, Perea S, Kirkpatrick WR, Peman J, Patterson TF, Martinez JP, L?pez-Ribot JL. The C-terminal antibody binding domain of Candida albicans mp58 represents a protective epitope during candidiasis. FEMS Microbiol Lett. 2004 Mar 19; 232(2):133-8.
    View in: PubMed
    Score: 0.018
  19. Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell. 2003 Oct; 2(5):1053-60.
    View in: PubMed
    Score: 0.018
  20. Ramage G, Saville SP, Wickes BL, L?pez-Ribot JL. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol. 2002 Nov; 68(11):5459-63.
    View in: PubMed
    Score: 0.017
  21. Viudes A, Perea S, Lopez-Ribot JL. Identification of continuous B-cell epitopes on the protein moiety of the 58-kiloDalton cell wall mannoprotein of Candida albicans belonging to a family of immunodominant fungal antigens. Infect Immun. 2001 May; 69(5):2909-19.
    View in: PubMed
    Score: 0.015
  22. Campuzano A, Zhang H, Ostroff GR, Dos Santos Dias L, W?thrich M, Klein BS, Yu JJ, Lara HH, Lopez-Ribot JL, Hung CY. CARD9-Associated Dectin-1 and Dectin-2 Are Required for Protective Immunity of a Multivalent Vaccine against Coccidioides posadasii Infection. J Immunol. 2020 06 15; 204(12):3296-3306.
    View in: PubMed
    Score: 0.014
  23. Banerjee M, Lazzell AL, Romo JA, Lopez-Ribot JL, Kadosh D. Filamentation Is Associated with Reduced Pathogenicity of Multiple Non-albicans Candida Species. mSphere. 2019 10 16; 4(5).
    View in: PubMed
    Score: 0.014
  24. Wall G, Montelongo-Jauregui D, Vidal Bonifacio B, Lopez-Ribot JL, Uppuluri P. Candida albicans biofilm growth and dispersal: contributions to pathogenesis. Curr Opin Microbiol. 2019 12; 52:1-6.
    View in: PubMed
    Score: 0.013
  25. Dekkerov? J, Lopez-Ribot JL, Bujd?kov? H. Activity of anti-CR3-RP polyclonal antibody against biofilms formed by Candida auris, a multidrug-resistant emerging fungal pathogen. Eur J Clin Microbiol Infect Dis. 2019 Jan; 38(1):101-108.
    View in: PubMed
    Score: 0.013
  26. Liu NN, Uppuluri P, Broggi A, Besold A, Ryman K, Kambara H, Solis N, Lorenz V, Qi W, Acosta-Zald?var M, Emami SN, Bao B, An D, Bonilla FA, Sola-Visner M, Filler SG, Luo HR, Engstr?m Y, Ljungdahl PO, Culotta VC, Zanoni I, Lopez-Ribot JL, K?hler JR. Intersection of phosphate transport, oxidative stress and TOR signalling in Candida albicans virulence. PLoS Pathog. 2018 07; 14(7):e1007076.
    View in: PubMed
    Score: 0.012
  27. Cleary IA, Reinhard SM, Lazzell AL, Monteagudo C, Thomas DP, Lopez-Ribot JL, Saville SP. Examination of the pathogenic potential of Candida albicans filamentous cells in an animal model of haematogenously disseminated candidiasis. FEMS Yeast Res. 2016 Mar; 16(2):fow011.
    View in: PubMed
    Score: 0.010
  28. Albataineh MT, Lazzell A, Lopez-Ribot JL, Kadosh D. Ppg1, a PP2A-type protein phosphatase, controls filament extension and virulence in Candida albicans. Eukaryot Cell. 2014 Dec; 13(12):1538-47.
    View in: PubMed
    Score: 0.010
  29. Chaturvedi AK, Hameed RS, Wozniak KL, Hole CR, Leopold Wager CM, Weintraub ST, Lopez-Ribot JL, Wormley FL. Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice. PLoS One. 2014; 9(8):e104316.
    View in: PubMed
    Score: 0.009
  30. Chaturvedi AK, Weintraub ST, Lopez-Ribot JL, Wormley FL. Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses. Proteomics. 2013 Dec; 13(23-24):3429-41.
    View in: PubMed
    Score: 0.009
  31. Chambers JP, Yu JJ, Jupelli M, Weintraub ST, Lopez-Ribot JL, Valdes JJ, Arulanandam BP. Alpha-1 antitrypsin is markedly decreased following pulmonary F. tularensis challenge. Front Cell Infect Microbiol. 2011; 1:20.
    View in: PubMed
    Score: 0.008
  32. Martins M, Lazzell AL, Lopez-Ribot JL, Henriques M, Oliveira R. Effect of exogenous administration of Candida albicans autoregulatory alcohols in a murine model of hematogenously disseminated candidiasis. J Basic Microbiol. 2012 Aug; 52(4):487-91.
    View in: PubMed
    Score: 0.008
  33. Carlisle PL, Banerjee M, Lazzell A, Monteagudo C, L?pez-Ribot JL, Kadosh D. Expression levels of a filament-specific transcriptional regulator are sufficient to determine Candida albicans morphology and virulence. Proc Natl Acad Sci U S A. 2009 Jan 13; 106(2):599-604.
    View in: PubMed
    Score: 0.006
  34. Banerjee M, Thompson DS, Lazzell A, Carlisle PL, Pierce C, Monteagudo C, L?pez-Ribot JL, Kadosh D. UME6, a novel filament-specific regulator of Candida albicans hyphal extension and virulence. Mol Biol Cell. 2008 Apr; 19(4):1354-65.
    View in: PubMed
    Score: 0.006
  35. Saville SP, Lazzell AL, Bryant AP, Fretzen A, Monreal A, Solberg EO, Monteagudo C, Lopez-Ribot JL, Milne GT. Inhibition of filamentation can be used to treat disseminated candidiasis. Antimicrob Agents Chemother. 2006 Oct; 50(10):3312-6.
    View in: PubMed
    Score: 0.005
  36. Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis. 2006 Apr 01; 193(7):1014-22.
    View in: PubMed
    Score: 0.005
  37. Ullmann BD, Myers H, Chiranand W, Lazzell AL, Zhao Q, Vega LA, Lopez-Ribot JL, Gardner PR, Gustin MC. Inducible defense mechanism against nitric oxide in Candida albicans. Eukaryot Cell. 2004 Jun; 3(3):715-23.
    View in: PubMed
    Score: 0.005
  38. Hernandez S, L?pez-Ribot JL, Najvar LK, McCarthy DI, Bocanegra R, Graybill JR. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob Agents Chemother. 2004 Apr; 48(4):1382-3.
    View in: PubMed
    Score: 0.005
  39. Sepulveda P, Lopez-Ribot JL, Gozalbo D, Cervera A, Martinez JP, Chaffin WL. Ubiquitin-like epitopes associated with Candida albicans cell surface receptors. Infect Immun. 1996 Oct; 64(10):4406-8.
    View in: PubMed
    Score: 0.003
  40. Sepulveda P, Cervera AM, Lopez-Ribot JL, Chaffin WL, Martinez JP, Gozalbo D. Cloning and characterization of a cDNA coding for Candida albicans polyubiquitin. J Med Vet Mycol. 1996 Sep-Oct; 34(5):315-22.
    View in: PubMed
    Score: 0.003
  41. Casanova M, Lopez-Ribot JL, Monteagudo C, Llombart-Bosch A, Sentandreu R, Martinez JP. Identification of a 58-kilodalton cell surface fibrinogen-binding mannoprotein from Candida albicans. Infect Immun. 1992 Oct; 60(10):4221-9.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support